Back to Peripheral T-Cell Lymphoma, Not Otherwise Specified

Peripheral T-Cell Lymphoma, Not Otherwise Specified — Clinical Trials

MONDO:000496448 active·32 recruitingLast updated: Mar 20, 2026, 9:48 AM

Trial Landscape

Peripheral T-Cell Lymphoma, Not Otherwise Specified has an active clinical trial landscape, driven by drug treatment and biological therapy.

Recruiting

Active Trials

By Approach

Drug Treatment46

Biological Therapy12

Procedure10

Medical Device1

17 additional trials involve behavioral, dietary, diagnostic, or observational approaches.

By Phase

Early Phase 1

Phase 1

Phase 2

Phase 3

12 trials are observational or have no phase designation.

Sponsor Types

Academic/Other47Industry11NIH2Collaborative Network1

Top Sponsors

BioInvent International AB

Boston Immune Technologies and Therapeutics

Corvus Pharmaceuticals, Inc.

Dizal Pharmaceuticals

Jiangsu HengRui Medicine Co., Ltd.

SciTech Development, Inc.

Trial Locations

United States37 trials

China15 trials

Denmark3 trials

Italy2 trials

Spain2 trials

United Kingdom2 trials

Taiwan2 trials

Canada2 trials

South Korea2 trials

Romania1 trial

Trials often recruit across multiple countries, so totals exceed the trial count.

61 Trials

Phase 3Recruiting

NCT06561048

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Sponsor:Corvus Pharmaceuticals, Inc.

United StatesStarted: Oct 2024Est. completion: Jul 2028Updated: Mar 2026

Phase 3Recruiting

NCT07234162

A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)

Sponsor:Dizal Pharmaceuticals

ChinaStarted: May 2024Est. completion: Oct 2028Updated: Nov 2025

Phase 3Recruiting

NCT05075460

Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma

Sponsor:Peking Union Medical College Hospital

ChinaStarted: Oct 2021Est. completion: Oct 2024Updated: Apr 2024

Last updated over 18 months ago

Phase 2Recruiting

NCT06390319

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

Sponsor:St. Jude Children's Research Hospital

United StatesStarted: Dec 2024Est. completion: Dec 2033Updated: Feb 2026

Phase 2Recruiting

NCT07356245

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

Sponsor:Jonathan Brammer

United StatesStarted: Feb 2026Est. completion: Jan 2027Updated: Jan 2026

Phase 2Recruiting

NCT05996185

Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

Sponsor:Yale University

United StatesStarted: Oct 2024Est. completion: Nov 2027Updated: Dec 2025

Phase 2Recruiting

NCT07283822

Amping up With PemJAK

Sponsor:Seda S. Tolu

United StatesStarted: Dec 2025Est. completion: Jan 2029Updated: Dec 2025

Phase 2Recruiting

NCT05313243

Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma

Sponsor:Yale University

United StatesStarted: Jul 2023Est. completion: Jul 2028Updated: Mar 2025

Phase 2Recruiting

NCT05477264

Concurrent Tislelizumab and Radiotherapy in Newly Diagnosed Extranodal NK/T-cell Lymphoma, Nasal Type

Sponsor:Won Seog Kim

South KoreaStarted: Mar 2023Est. completion: Dec 2026Updated: Apr 2024

Last updated over 18 months ago

Phase 2Recruiting

NCT04922567

Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

Sponsor:Second Affiliated Hospital, School of Medicine, Zhejiang University

ChinaStarted: Apr 2021Est. completion: Dec 2026Updated: Nov 2022

Last updated over 18 months ago

Phase 2Active, Not Recruiting

NCT01352520

SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)

Sponsor:M.D. Anderson Cancer Center

United StatesStarted: Jun 2011Est. completion: Jan 2028Updated: Jan 2026

Phase 2Active, Not Recruiting

NCT03113500

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma

Sponsor:City of Hope Medical Center

United StatesStarted: May 2017Est. completion: Jul 2026Updated: Nov 2025

Phase 2Active, Not Recruiting

NCT05673785

A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)

Sponsor:Takeda

ChinaStarted: Feb 2023Est. completion: Dec 2027Updated: Jul 2025

Phase 2Active, Not Recruiting

NCT00544115

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

Sponsor:City of Hope Medical Center

Started: Oct 2001Est. completion: Apr 2026Updated: Jun 2025

Phase 2Active, Not Recruiting

NCT02232516

Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma

Sponsor:Northwestern University

United StatesStarted: Jun 2015Est. completion: Aug 2024Updated: Apr 2024

Last updated over 18 months ago

Phase 1Active, Not Recruiting

NCT03278782

Study of Pembrolizumab (MK-3475) in Combination With Romidepsin

Sponsor:M.D. Anderson Cancer Center

United StatesStarted: Nov 2017Est. completion: Jul 2027Updated: Jan 2026

Phase 1Active, Not Recruiting

NCT03602157

Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL

Sponsor:UNC Lineberger Comprehensive Cancer Center

United StatesStarted: Dec 2018Est. completion: Nov 2039Updated: Jan 2026

Phase 1Active, Not Recruiting

NCT03011814

Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

Sponsor:City of Hope Medical Center

United StatesStarted: Mar 2017Est. completion: Aug 2026Updated: Sep 2025

Phase 1Active, Not Recruiting

NCT03598998

Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas

Sponsor:City of Hope Medical Center

United StatesStarted: Feb 2019Est. completion: Feb 2026Updated: Jun 2025

Phase 1Active, Not Recruiting

NCT03952078

A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma

Sponsor:Corvus Pharmaceuticals, Inc.

United StatesStarted: May 2019Est. completion: Apr 2026Updated: Apr 2025

Stay informed about clinical trials for Peripheral T-Cell Lymphoma, Not Otherwise Specified.

Follow this disease to get updates when trials open, close, or change status.

Follow This Disease — Free

Already have an account? Sign in to manage your watchlists.

Data sourced from ClinicalTrials.gov via Kisho's automated pipeline. Trials refreshed every 4 hours for monitored diseases.

Last sync: March 20, 2026 at 9:48 AM

Peripheral T-Cell Lymphoma, Not Otherwise Specified — Clinical Trials

Trial Landscape

By Approach

By Phase

Sponsor Types

Top Sponsors

Trial Locations

61 Trials

Open Trials37

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)

Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

Amping up With PemJAK

Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma

Concurrent Tislelizumab and Radiotherapy in Newly Diagnosed Extranodal NK/T-cell Lymphoma, Nasal Type

Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

Active Trials11

SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma

A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma

Study of Pembrolizumab (MK-3475) in Combination With Romidepsin

Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL

Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas

A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma

Other13